Department of Otorhinolaryngology, Academic Medical Center, Amsterdam, the Netherlands.
Rhinology. 2020 Feb 1;58(1):1. doi: 10.4193/Rhin20.401.
Together with this issue of Rhinology the new European Position Paper on Rhinosinusitis and Nasal Polyps will see the light. The European Position Paper on Rhinosinusitis and Nasal Polyps 2020 is the update of similar evidence based position papers published in 2005 and 2007 and 2012. The core objective of the EPOS2020 guideline is to provide revised, up-to-date and clear evidence-based recommendations and integrated care pathways in ARS and CRS. EPOS2020 provides an update on the literature published and studies undertaken in the eight years since the EPOS2012 position paper was published and addresses areas not extensively covered in EPOS2012 like paediatric CRS, sinus surgery, exacerbations of CRS and the prevention of CRS. EPOS2020 also involved new stakeholders, like neurologists, immunologists, pharmacists and patients and address new target users who have become more involved in the management and treatment of rhinosinusitis since the publication of the last EPOS document, including pharmacists, nurses, specialised care givers and indeed patients themselves, who employ increasing self-management of their condition using over the counter treatments. The document provides suggestion for future research in this area and offer updated guidance for definitions and outcome measurements in research in different settings.
本期《鼻科学》杂志将同时推出新的《欧洲鼻窦炎和鼻息肉意见书》。2020 年的《欧洲鼻窦炎和鼻息肉意见书》是对 2005 年、2007 年和 2012 年发布的类似循证立场文件的更新。EPOS2020 指南的核心目标是提供修订后的、最新的和清晰的循证推荐和综合护理路径，以治疗 ARS 和 CRS。EPOS2020 更新了自 EPOS2012 立场文件发布以来 8 年内发表的文献和开展的研究，并涵盖了 EPOS2012 未广泛涉及的领域，如儿科 CRS、鼻窦手术、CRS 恶化和 CRS 的预防。EPOS2020 还涉及新的利益相关者，如神经学家、免疫学家、药剂师和患者，并针对自上次 EPOS 文件发布以来更多参与鼻窦炎管理和治疗的新目标用户，包括药剂师、护士、专门护理人员，甚至是患者自己，他们越来越多地使用非处方治疗来自我管理病情。该文件为该领域的未来研究提供了建议，并为不同环境下的研究提供了更新的定义和结果测量指导。
